December 6th, 2007, by Digital Davo | oracea, tetracyclines
A recent investor presentation from Collagenex shows some interesting insights into how Collagenex are promoting Oracea. Oracea is promoted as safe and effective for long term use. It was reported that the average duration of Oracea therapy is 4 months, compared to an average of 2.5 months for other rosacea prescriptions. 52% of Oracea prescriptions are refills - the presentation suggests that …
September 27th, 2007, by Digital Davo | tetracyclines
Despite promising looking Phase 1 and initial Phase 2 dose finding studies, Incyclinide will no longer be developed as a treatment for rosacea. Incyclinide is a chemically modified tetracycline that its developers - Collagenex, was hoping would become another systemic treatment for rosacea. We did get a warning in May that clinical trials for Incyclinide weren’t all going smoothly - when the …
May 22nd, 2007, by Digital Davo | tetracyclines
Collagenex has announced that their ongoing trials to find the best dosage for Incyclinide have discovered that 40mg can cause photo-toxicity.
Collagenex is conducting parallel Phase II trials for Incyclinide for both acne and rosacea.
As detailed in a recent news item, incyclinide targets conditions other than rosacea, Incyclinide differs from a non-antibiotic tetracycline in that it is also chemically modified. Thus we might expect that …
April 24th, 2007, by Digital Davo | tetracyclines
There has been a lot of publicity lately about Oracea, which is a low dosage, sustained release 40mg form of doxycyline. Oracea was born out of the expiration of the patent on periostat - a twice a day 20mg dose of doxycycline originally targetted at gum disease. Another new low dose antiobiotic is Solodyn (45mg, 90mg and 135mg of extended release minocycline HCL, dose …
April 20th, 2007, by Digital Davo | tetracyclines
This article, just published is adding to body of research of the anti-inflammatory actions of the tetracycline family. Recent related studies have been undertaken during the development of low dose doxycycline, for eg. oracea. So far this abstract isn’t teasing us with anything new. A similarly titled paper from 2006, Tetracyclines: their non-antibiotic properties also addressed this topic. Anti-Inflammatory Activity …
|
|
|
|
|
|
|
|
|